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Abstract
Purpose A randomized controlled trial of thymectomy in myasthenia gravis demonstrated improved clinical outcomes in
adults, but data surrounding juvenile cases, especially those treated with minimally invasive approaches, are limited. Here,
we review our experience with thoracoscopic thymectomy for juvenile myasthenia gravis (JMG) in the largest cohort to date.
Methods All cases of thymectomy for JMG in a single tertiary referral center between 2007 and 2018 were reviewed
(N = 50). Patients underwent left thoracoscopic approach with extended dissection and without use of monopolar energy.
Demographics, diagnostic criteria, and clinical classification, as well as surgical data were collected. Clinical status and
medications were reviewed in follow-up.
Results The mean age at surgery was 10.5 ± 0.8 years. Ocular disease and generalized disease each comprised half of the
cohort. No patients suffered complications or increased risk of morbidity or mortality with thymectomy. At any interval of
follow-up through 3.5 years, 49.8% of patients were improved compared to their pre-operative presentation, and there was
a significant trend towards decreased steroid use.
Conclusion Thoracoscopic thymectomy is a safe treatment for juvenile myasthenia gravis in pediatric patients over a wide
range of ages, body masses, and symptoms. Our experience adds evidence that pediatric patients likely benefit from thymectomy with improved clinical status and reduced medications.
Keywords Minimally invasive surgery · Thoracoscopy · Thymectomy · Juvenile myasthenia gravis
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Myasthenia gravis (MG) is an autoimmune disease characterized by the production of antibodies against acetylcholine
receptors (AChR) in the neuromuscular junction. Patients
experience debilitating fluctuating weakness of various muscle groups, e.g. ocular, facial, limb, swallowing, or respiratory, and symptoms are exacerbated by activity and stress.
In childhood, the disease presents in two forms, transient
neonatal MG and juvenile MG (JMG). Twenty percent of
babies born to women with MG exhibit transient neonatal
MG with hypotonia and feeding difficulties that usually
resolve within 2 months with supportive therapy [1]. JMG
comprises a subset of patients exclusive of the transient form
in whom symptom onset occurs before 18 years of age.
JMG is diagnosed by clinical presentation supported by
laboratory assessment of antibodies (predominantly AChR,
but also muscle-specific kinase (MuSK)) and neuromuscular testing to evaluate for electrodecrement on repetitive nerve stimulation. There is no evidence to indicate
that pathophysiology differs between JMG and adult onset
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MG. Retrospective and longitudinal studies in the pediatric
population have shown children with MG are more likely to
present with ocular symptoms, and the estimated frequency
of generalized disease ranges from 29 to 75%, which is less
than is reported in the adult population [2]. However, ocular
disease may progress to generalized symptoms in 30–50%
of pediatric/adolescent patients [3]. Spontaneous remission
may be more likely in JMG at 14.3–45% compared to adultonset disease [4, 5]. Consensus on management of JMG is
further complicated by differences in presentation, disease
course, and response to treatment as related to gender, race,
age of onset, and antibody status [6–8].
This variability compounded with the low incidence of
JMG and the ethical challenges of pediatric trials have thus
far prohibited large-scale prospective studies and development of strong evidence-based practice guidelines.
Treatment for JMG broadly follows adult MG guidelines.
First-line therapy is with acetylcholine esterase inhibitors
(AChEI), which may suffice for ocular-only disease. Immunosuppressive agents and immunomodulating therapy are
added for refractory or progressing disease. With development of generalized muscle weakness, a multimodal
approach is indicated including AChEI, immunosuppressive
agents, immunomodulating therapy, and surgery [9].
Thymectomy offers improved chance of remission,
reduction in medical therapy and its complications (e.g.
from long-term steroid use), and reduced risk of progression of disease. These effects are well described in the adult
literature with evidence suggesting that MG patients after
thymectomy are more likely to achieve symptom-free, medication-free remission. Those with severe and generalized
symptoms and those undergoing “early” thymectomy may
have a better chance of remission [10]. A recent multicenter
randomized trial in adults comparing thymectomy with
steroid therapy versus steroid therapy alone demonstrated
superior clinical outcomes (lower Quantitative Myasthenia
Gravis score, decreased medication usage, and fewer hospitalizations) in the thymectomy cohort over a 3-year period
[11]. Different approaches (transsternal, transcervical, thoracoscopic) have been investigated, and generally show similar
efficacy [12, 13].
In the pediatric literature, multiple retrospective studies have supported thymectomy for peri-pubertal and postpubertal AChR-positive JMG with moderate to severe symptoms. A recent systematic review of 16 studies recorded
post-operative improvement in JMG severity in 77% of
patients, including 29% with complete sustained remission
[14]. Similar to adults, “early thymectomy” (performed
within a year of diagnosis) resulted in higher remission
rates compared to “late thymectomy” [15, 16]. Support
for thymectomy in JMG includes minimizing the adverse
effects of immunosuppression such as growth retardation
and returning patients to baseline neurological function as
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soon as possible to prevent potential developmental delays.
Thoracoscopic thymectomy offers significant benefits with
reports of few complications, shorter hospital stays, and better aesthetic outcomes, but raises the risk of a potentially
incomplete resection [17–19].
Here we present our experience with a minimally invasive surgical approach for thymectomy in the pediatric
population.

Methods
Institutional Review Board approval (#14-011298) was
obtained for the study. A retrospective review of all patients
undergoing thymectomy for the treatment of myasthenia
gravis was performed at a single tertiary referral center
between 2007 and 2018 (N = 50). Medical records were
examined for patient demographics, clinical presentation,
medical management, time to surgical intervention, and indication for surgery, as well as operative and post-operative
data. Patients for whom pre-operative and follow-up visits
were available had their charts reviewed and abstracted for
inpatient or outpatient visits at half-year intervals. Data were
not uniformly available for all post-operative intervals in
this retrospective review; visits were assigned to the halfyear time-point to which it was closest (within 3 months).
Patients’ clinical state was compared to their pre-operative
condition. Disease severity was assessed as documented
in the physical exam performed by Neurologists or Ophthalmologists and graded per criteria from the Myasthenia Gravis Foundation of America Postintervention Status
(MGFA-PIS) and the DeFilippi classification. The MGFAPIS defines an “improved (I)” change in status compared to
pre-intervention as “A substantial decrease in pretreatment
clinical manifestations or a sustained substantial reduction in MG medications as defined in the protocol” [20].
We defined a “substantial reduction in MG medications”
as a 50% decrease in medication dose. Under the DeFilippi
designations, Classes 1–3 all describe a favorable clinical
state, with 1 being “Complete remission off all medications”, 2 for “Asymptomatic on decreased medications”,
and 3, “Improved, with decreased symptoms or decreased
medications” [21]. Weight-adjusted daily medication doses
were calculated for all patients on steroids (prednisone or
prednisolone) and for whom weights were documented at
the appropriate follow-up visit.
Descriptive statistics were utilized throughout to summarize demographic, perioperative, and outcome data,
presenting means ± standard error of the mean (SEM)
unless otherwise indicated. A Kaplan–Meier event curve
was generated using MGFA-PIS “Improved” status as the
“event” captured at the time of final follow-up and calculating cumulative probabilities. One-way ANOVA and linear
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regression analyses were applied to evaluate trends in medication dosing throughout follow-up. All statistical analyses
were performed using Microsoft Excel and GraphPad Prism
version 7.0 for Mac. Statistical significance was interpreted
at p < 0.05.

Surgical technique
Patients were positioned supine with a small bump under
the left chest, and the left arm gently abducted and padded
(Fig. 1a). Single lung ventilation was not used; instead,
low pressure CO2 insufflation (< 6 mmHg) and PEEP < 2
allowed functional isolation while gravity effectively
retracted the lung. Three 5-mm trocars were placed using
a blunt or optical technique (Fig. 1b). The left phrenic
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nerve was identified and preserved. All dissections were
blunt, cold, sharp, or with the Ligasure™ (Covidien, Dublin, Republic of Ireland) bipolar device. After opening the
pleura over the thymus and allowing the phrenic nerve
to fall posteriorly with the associated pleura, the inferior
poles were freed, taking care to include associated pericardial fat. The largely avascular planes above and below the
thymus were also developed mostly with blunt dissection,
working across the mediastinum. The contralateral pleura
can be seen as a white line when the thymus is retracted
toward the left hemi-thorax, and the plane between thymus and right pleura was gently developed bluntly. Then
when the inferior poles were largely free, the innominate
vein was identified and skeletonized, dividing the one or
two draining veins from the thymus using the Ligasure.

Fig. 1  a Patient positioned with bump under the left chest and left arm gently abducted. b Diagram depicting port placement and operative
approach. c Laparoscopic view of the thymus (dashed line) and the course of the phrenic nerve (dotted line)
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Occasionally, small feeding arteries can be identified in the
loose tissue anteriorly, and these were also divided with
the Ligasure. The superior horns were then traced well
up into the neck until they tapered down to thin connective tissue often with lymphatic tissue associated. These
poles were also divided with the Ligasure. The thymus was
retrieved using an endoscopic specimen bag. The anterior
mediastinum was inspected to ensure that it had been skeletonized and no residual thymus remained. Residual CO2
was evacuated with a chest tube pulled before closing the
last trocar incision with a static positive pressure breath
administered by the anesthesiologist.

Results
Demographics
The mean age at diagnosis was 8.8 years ± 0.8 (range
1–17 years) (Table 1). The majority of patients were
female (72.0%). Just over half of patients (54.5%) exhibited generalized symptoms. The majority were on pyridostigmine and steroids (prednisone or prednisolone), and
half of patients were on both. Approximately, a third of
patients (34.1%) were on chronic intravenous immunoglobulin (IVIG) therapy.
The two most common indications for thymectomy
were failure of medical therapy and generalized/bulbar
symptoms (Table 2). The former indication included
patients in whom symptoms were not controlled on escalating medical therapy and those in whom steroids could
not be weaned.

Table 2  Indications for thymectomy
Failure of medical therapy (%)
Systemic/bulbar symptoms (%)
Increase chance of remission/reduce meds (%)
Suspected thymic abnormality (%)
Reason not specified (%)

27.3
27.3
22.7
11.4
11.4

Perioperative data
The mean age at surgery was 10.5 years ± 0.8 (range of
3–17 years) (Table 3). Consistent with the wide age range,
patients exhibited a range of weights and a mean body mass
index (BMI) of 22.3 ± 1.0 (range 13.0–49.6). On average, patients were on medical therapy prior to surgery for
19.6 months ± 4.2 (n = 49, range of 0–168 months), and 51%
of patients had an “early thymectomy,” defined as occurring
within 1 year of diagnosis.

Surgical outcomes
The mean operative time was 104 min ± 3.5 (range of
62–163 min). Patients stayed in the hospital a mean of 1.2
days ± 0.1 after surgery with 86% of patients being discharged on post-operative day 1. Nine patients (18%) were
admitted to the intensive care unit (ICU) post-operatively.
There were no complications: no conversions to thoracotomy, no median sternotomy, no significant blood loss,
no transfusions, no prolonged intubations, and no re-intubations. No thymomas were identified in any pathological
specimen. Approximately half of specimens were normal
on histopathology (52%) and less than one-third (30.0%)
displayed thymic hyperplasia.

Table 1  Demographics
Age at diagnosis (n = 49)
≤ 10 years old (%)
11–18 years old (%)
Gender
Female (%)
Male (%)
Seropositivity
AchR (%) (n = 48)
Classification at pre-op (n = 44)
Ocular (%)
Generalized (%)
Management at pre-op (n = 44)
Pyridostigmine (%)
Steroids (%)
Chronic IVIG (%)
Plasmapheresis (%)
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8.8 ± 0.8
55.1
44.9
72.0
28.0
62.5
45.5
54.5
77.3
65.9
34.1
9.1

Table 3  Perioperative and surgical data
Age at surgery (n = 50)
BMI at surgery (n = 49)
Time to thymectomy (months) (n = 49)
Early thymectomy (%)
Pre-op conditioning with IVIG (%)
Operative time (min)
Estimated blood loss (mL)
Post-operative ICU admission (%)
Complications (%)
Post-operative stay (days)
Histopathology
Normal (%)
Thymic hyperplasia (%)
Thymoma (%)
Other (%)

10.5 ± 0.8
22.3 ± 1.0
19.6 ± 4.2
51.0
42.0
104 ± 3.5
2.9 ± 0.3
18.0
0
1.2 ± 0.1
52.0
30.0
0
18.0
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Clinical outcomes
Follow-up data were available for 41 patients and ranged
from 1 to 11 years post-operatively. Thirty-five patients had
pre-operative and follow-up data, with a mean of 79.3% of
patients returning for follow-up through 3.5 years, excluding those who re-located or transitioned to adult care at ≥
18 years of age (mean follow-up duration 37.9 ± 4.2 months)
(Fig. 2). After 3.5 years, the percentage of patients with follow-up data acutely declined to less than 50%, resulting in
a sample size too small for reliable statistical assessment of
outcomes.
A mean of 49.8% of patients showed an “Improved”
MGFA-PIS change in status compared to prior to surgery
through 3.5 years of post-operative follow-up (Fig. 3). Using
the DeFilippi classification over the same period, a mean
of 61.9% of patients scored within classes 1 to 3, demonstrating improvement either by clinical symptomatology or
decreased medication requirements (data not shown). There
was no statistically significant difference in the percentage
of “Improved” patients when the cohort was stratified for
ocular versus generalized type, age at thymectomy, or timing of thymectomy. A Kaplan–Meier event curve looking
specifically at those with follow-up through 3.5 years after
thymectomy at their last recorded visit shows an increasing
cumulative probability of “Improved” status (Fig. 4).
Of the 35 patients in whom pre- and post-operative
data are available, none were on any non-steroid oral

Fig. 2  An average of 79.3% of patients in whom pre- and post-operative data were available presented for follow-up at any given 6-month
interval between 0.5 and 3.5 years after thymectomy; the gray bars
depict the number of patients due for follow-up (excluding those who
relocated or transitioned to adult care at ≥ 18 years of age), the black
bars depict the number of those that presented for follow-up

Fig. 3  At any given half-year follow-up between 6 and 42 months
after surgery, a mean of 49.8% of patients were “improved” compared
to their pre-operative status, as defined by the MGFA-PIS classification with substantial decrease in clinical symptoms or 50% reduction
in medications

immunosuppressive agent at the time of surgery. Eight
patients were initiated on an agent post-operatively (seven
on azathioprine and one on mycophenolic acid). All but
one patient were on an agent at the last available followup visit. Looking specifically at weight-adjusted daily total
steroid dose, there was no statistically significant difference
by one-way ANOVA over 3.5 years of follow-up. On linear regression analysis, however, total daily steroid intake
(p = 0.0027) decreased significantly over the same follow-up

Fig. 4  Kaplan–Meier event curve for “Improved” clinical status by
MGFA-PIS classification at last follow-up visit with the number of
patients “at risk” at each time-point depicts increasing cumulative
probability of “improved” clinical status after thymectomy
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period (Fig. 5). There was no significant difference in the
proportion of patients on pyridostigmine therapy at the time
of surgery compared to that in follow-up.

Discussion
This series reports on the largest cohort of thoracoscopic
pediatric thymectomy cases with 79% adherence to longterm post-operative follow-up, providing more robust
evidence than has been published to date. In a cohort of
variable ages, disease severities, and timing to operative
intervention, there were no adverse events and the majority of patients were discharged 1 day after surgery. At any
given half-year follow-up interval between 6 months and
3.5 years after surgery, half of patients demonstrated clinical
improvement compared to their pre-operative state, either
with decreased symptoms and/or medications. Finally, we
report a significant trend towards decreased weight-based
steroid dosing after thymectomy. This study adds substantial
weight of evidence for the safety of thoracoscopic thymectomy and its place in the clinical management of JMG.
The role of thymectomy for adult MG, already a wellestablished treatment modality, was recently validated in
a randomized controlled trial (RCT) as superior treatment
compared to steroid therapy alone in achieving symptom
resolution, decreasing total steroid dose, and enhancing
quality of life [11]. Studies in the JMG population are far
less robust, though multiple retrospective analyses have
shown both open and minimally invasive approaches to be
safe and effective in children [17, 18, 22]. Thoracoscopic
series are fewer in number, but suggest benefits of decreased
estimated blood loss, shorter hospital stays, and improved
cosmesis [23, 24]. Madenci et al. in 2017 published a systematic review of the literature from 2000 to 2016 regarding thymectomy for the treatment of JMG [14]. In 16

Fig. 5  Weight-adjusted total daily steroid intake (mg/kg/day)
decreased significantly over 3.5 years of follow-up on linear regression analysis
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retrospective studies including 1131 pediatric patients of
which 43% underwent thymectomy, 77% exhibited improvement in JMG severity after thymectomy with 2–5 years of
follow-up. The majority of studies reported on the open
transsternal approach (82% of patients) and four studies
compared surgical approaches, with insufficient power for
statistical comparison. Few studies compared outcomes of
patients who underwent thymectomy against those that did
not—and their findings were mixed.
In our cohort, a smaller percentage of patients exhibited
“improved” clinical status compared to what is reported
by Madenci et al. (50% versus 77%). We attribute this difference to the application of a more stringent definition
of “clinical improvement.” Change in clinical status was
evaluated according to the MGFA-PIS classification system
and relied on the documented physical exam of the treating neurologist or ophthalmologist and/or a 50% decrease
in medication dosage documented at the follow-up visit.
When evaluating the same cohort by the DeFilippi system,
which does not use objective measures for grading, we also
observed a higher mean percentage of patients designated
as “improved” compared to that determined by MGFA-PIS.
Despite the increased sample size, our study is insufficiently
powered for statistical demonstration of remission, defined
by the MGFA as “no symptoms or signs of MG for at least
1 year and… no therapy for MG during that time” [20].
Remission patterns in JMG have been shown to wax and
wane, significantly affected by external stressors and illness,
but with an overall trend towards greater improvement further out from surgery [23, 25]. Longitudinal follow-up of
this population will be required to determine true effectiveness of operative intervention here.
Another significant finding in the data involved decreasing medications in patients after thymectomy. Medical management of JMG long term is not benign, especially in the
pediatric patient, as therapy can result in side effects both
inconvenient and detrimental to growth and development
during a critical period. Over a fifth of patients underwent
surgery to reduce medications; though this result has been
observed in the pediatric literature, no statistically significant difference had yet been demonstrated in JMG. We found
weight-adjusted total daily steroid intake declined significantly over the course of follow-up on linear regression analysis. This result is notable in light of the significant adverse
effects of steroids on development and growth. As well, our
data suggest a larger sample size and longer follow-up in a
pediatric RCT may recapitulate the findings in the adult RCT
in which the time-weighted average prednisone dose was
significantly lower in patients after thymectomy compared
to those on medical management alone.
In the adult literature early thymectomy for ocular MG
has been promoted to prevent onset of generalized symptoms [26]. Thymectomy for ocular MG in children is
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controversial. About 1/3 of ocular MG cases develop systemic symptoms but most progress through a relatively
benign course with medical management. Especially in
the pre-pubescent group, generalization seems to occur at
a much lower rate and spontaneous remission appears more
common [27]. In our series, 45.5% exhibited only ocular
symptoms at the time of surgery and none of these patients
converted to generalized disease in follow-up. Further, in
subgroup analysis of ocular versus generalized and thymectomy before or after 10 years of age, there was no significant
difference in the rates of improved clinical status. Again, a
larger group over longer follow-up may demonstrate differences in ultimate remission rates.
We exclusively utilize a left thoracoscopic approach,
which we found provides good mediastinal and cervical
exposure. Vigilant adherence to best practices of patient
positioning and good thoracoscopic principles allows accurate dissection of peri-thymic tissue while minimizing risk
to the patient. For example, the modified supine position
and gentle insufflation allows lung isolation without selective intubation. Similarly, exclusive use of smart bipolar
devices for hemostasis appears to reduce risk of thermal
damage to the phrenic nerves. Meanwhile, a stereotyped
dissection strategy minimizes anatomic confusion, reducing risk of damage to structures such as the innominate vein,
and diminishing the probability of performing an incomplete thymectomy. Some advocate for a bilateral approach,
but in the pediatric population, using an angled scope and
optimizing retraction provides excellent visualization of the
contralateral lobe (including any minor lobules) and the dissection comfortably carries to the contralateral pleura and to
the superior horns, even if these extend into the neck.
Retrospective analysis of a heterogeneous population with
a disease characterized by its variable fluctuating course is
a challenging cohort from which to draw inferences about
the study group as a whole. In particular, strong statements
about the effectiveness of thymectomy in different subgroups
cannot be made. Moreover, nothing can be said about optimal selection criteria—indications for surgery are not standardized, insufficient power exists among groups to discern
probability of response, and too few patients have follow-up
far enough to count most of those who will enter remission.
There also remains an open question as to whether or to
what degree thymectomy improves the probability of not
progressing from ocular to more generalized symptoms.
These questions leave the larger question of surgical indication incompletely answered. Given the published literature, there is certainly no consensus regarding the role nor
timing nor approach for thymectomy, and any patient with
a diagnosis of JMG may be considered for operative management. The published evidence suggests that we can say
with some confidence that thymectomy doubles or triples
the probability of remission compared to medical treatment
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alone. This would be best validated with a multi-center
randomized controlled trial in the pediatric JMG population. The experience of this larger group of patients with
broad ranges of body size, age, and presentation lends much
stronger support to the notion that a thoracoscopic approach
can be done without leaving residual thymic tissue and with
very low morbidity risk. Still, thoughtful consideration must
be given to the potential for large blood loss and permanent nerve damage, the inherent learning curve for pediatric
thoracoscopy, and the risk of persistent and worsening myasthenic symptoms even after surgery. Far greater numbers of
patients are needed to detect rare risks and to identify those
more likely to respond and achieve complete stable remission. To address this last concern, our intention is to develop
a JMG registry, with this group forming the initial seed.

Conclusion
Review of the largest series to date of thoracoscopic thymectomy for juvenile myasthenia gravis shows it is a safe and
effective adjunct in the treatment armamentarium, even for
ocular disease. Ongoing research will improve our understanding of rare risks, remission probability given different
disease presentations, and overall outcomes over longer time
scales. Development of a registry and continuing participation in multi-disciplinary efforts towards a pediatric randomized controlled trial are the next steps.
Funding This study was funded by the Department of General, Thoracic, and Fetal Surgery at The Children’s Hospital of Philadelphia.
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